Skip to main navigation Skip to search Skip to main content

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

  • on behalf of the REGAIN Study Group

Research output: Contribution to journal › Article › peer-review

Original languageEnglish
Pages (from-to)E610-E618
JournalNeurology
Volume96
Issue number4
DOIs
StatePublished - Jan 26 2021
Externally publishedYes

ASJC Scopus Subject Areas

  • Clinical Neurology

Cite this